Craft

CombiGene

Stock Price

KR1.8

2024-10-29

Market Capitalization

KR34.9 M

2024-10-29

CombiGene Summary

Company Summary

Overview
CombiGene is a gene therapy company. It specializes in preclinical studies including biodistribution and toxicology studies, development of GMP-classified manufacturing methods, scaling up production volumes and strategic regulatory work. The company focuses on the treatment of focal epilepsy and lipodystrophy.
Type
Public
Status
Active
Founded
2008
HQ
Lund, SE | view all locations
Website
https://combigene.com/
Cybersecurity rating
Sectors

Key People

  • Jan Nilsson

    Jan Nilsson, CEO & Director

    • Bert Junno

      Bert Junno, Chairman

      • Karin Agerman

        Karin Agerman, Chief Research and Development Officer

        • Peter Nilsson

          Peter Nilsson, Director

          LocationsView all

          1 location detected

          • Lund, Skåne län HQ

            Sweden

            Scheelevägen 2

          CombiGene Financials

          Summary Financials

          Gross profit (FY, 2025)
          kr573.0K
          Net income (FY, 2025)
          (kr12.4M)
          Cash (FY, 2025)
          kr2.6M
          EBIT (FY, 2025)
          (kr13.0M)

          Footer menu